Mahana Therapeutics has secured $61m in Series B financing to support commercialisation and further development of digital therapeutics.

The funds will be used by the company to introduce the FDA-cleared prescription digital therapeutic Mahana IBS, in addition to boosting the development of various digital therapeutics for chronic health conditions.

Led by JAZZ Venture Partners and Gurnet Point Capital, the financing round saw participation from new and existing investors Main Street Advisors, KKCG and Lux Capital. JAZZ and Lux led the firm’s earlier rounds.

With the latest funding, the company has taken its total capital raise to $81m to develop and commercialise its digital therapeutics product portfolio.

Gurnet Point’s Sophie Kornowski and JAZZ’s Meghan Reynolds have also joined the board of directors of Mahana Therapeutics.

Mahana Therapeutics CEO Steven Basta said: “We are grateful for the support of leading digital health, technology and life science investors who share our vision to empower patients with affordable, accessible, and effective digital tools to help patients manage their chronic conditions.

“We are fortunate at Mahana to have an extraordinary, dedicated team committed to serving patients with chronic disease. We sincerely thank the patients, clinicians and advisors who guide our development efforts and make our therapies possible.”

Mahana IBS is the prescription-only digital therapeutic device, which is designated as a three-month treatment offering cognitive behavioral therapy (CBT) to adults with irritable bowel syndrome (IBS). It is provided through an app on iOS and Android phones and tablets.

According to the company, Mahana IBS has showed effectiveness in a 558-patient clinical study in individuals with IBS.

Patients using the Mahana IBS programme demonstrated significant clinical improvement in IBS symptom severity, including less abdominal pain, bloating, bowel function dysregulation and adverse impact on daily social activities, said the company.

In November last year, the company secured de novo authorisation from the US Food and DrugAdministration (FDA) for the web version of Mahana IBS. In June this year, its mobile app version was approved.